Implications of the LIFE trial

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Research

Background:

• Essential hypertension is a major risk factor for cardiovascular disease.
• Left ventricular hypertrophy (LVH) is a common complication of hypertension, associated with increased cardiovascular risk.
• Current hypertension guidelines recommend various drug classes, but optimal first-line therapy remains debated.

Purpose of the Study:

• To compare the efficacy of losartan (an angiotensin receptor blocker) versus atenolol (a beta-blocker) in reducing cardiovascular morbidity and mortality in patients with essential hypertension and LVH.
• To assess the effects of both treatments on electrocardiographically-defined LVH regression.
• To evaluate the incidence of newly diagnosed diabetes in both treatment groups.

Main Methods:

• The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was a randomized, double-blind, controlled trial.
• Involved patients with essential hypertension and ECG evidence of LVH.
• Primary endpoint: composite of cardiovascular death, myocardial infarction, and stroke.

Main Results:

• Losartan significantly reduced the primary composite endpoint compared to atenolol.
• Losartan demonstrated a greater reduction in LVH compared to atenolol, despite similar blood pressure lowering.
• The atenolol group had a higher incidence of newly diagnosed diabetes.

Conclusions:

• Losartan, an angiotensin receptor blocker, is a highly effective treatment for hypertension, particularly in patients with LVH.
• Losartan offers significant cardiovascular benefits and LVH regression, potentially surpassing beta-blockers like atenolol.
• The findings challenge the role of beta-blockers as first-line monotherapy for hypertension and support the use of ARBs.